Symptomatic and disease-modifying therapies for multiple sclerosis: recent developments: highlights of the 9th Annual Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis, October 3, 2004, Toronto, Ontario, Canada.
Cook
Stuart D
SD
Department of Neurology and Neurosciences, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark, NJ, USA.
D015761:4-Aminopyridine / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D018849:Controlled Clinical Trials as Topic; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy*; D026902:Potassium Channel Blockers / Q000627:therapeutic use*; D011728:Pyridones / Q000627:therapeutic use*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D026902:Potassium Channel Blockers; D011728:Pyridones; D015761:4-Aminopyridine; C093844:pirfenidone